Skip to content

Human Intestinal Microbiota in Obesity and Nutritional Transition

Human Intestinal Microbiota in Obesity and Nutritional Transition

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01314690
Acronym
Micro-Obes
Enrollment
49
Registered
2011-03-14
Start date
2008-09-30
Completion date
2011-03-31
Last updated
2011-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, low calorie diet, intestinal microbiota, inflammation (systemic and in adipose tissue), fat mass, Impact of nutritional transition on intestinal microbiota, relation between food intake, clinical parameters and intestinal microbiota

Brief summary

The objectives of this study are: 1-To qualify the relationship between the gut microbiota and the host nutritional and metabolic status during dietary transition.2-To define the impact of nutritional transition on the intestinal microbiota and identify metagenomics signatures of nutritional transition.

Detailed description

French overweight (BMI \> 27) and obese people (BMI \> 30 kg/m2, N=50) will be submitted to a low calorie diet (1200 Kcal) for 8 weeks. This type of intervention is know to modify the metabolic phenotype and expected to change the gut microbiota. Nutritional interventions are planned for 6 months, each subject being studied before (base line), after the intervention (8 weeks) and 2 months after the low calorie diet has stopped and a diet of weight maintenance will be provided. This protocol will be implemented in the nutrition department of the Pitié Salpétrière Hospital in Paris, within the Centre de Recherche en Nutrition Humaine d'Ile-de-France, where patients will be followed on the clinical, biological and histological levels. Evaluation will include medical history, physical, and nutritional evaluations. They will be excluded of the protocol if they had evidence of acute or chronic inflammatory disease, infectious diseases, cancer and/or known alcohol consumption (\> 20g per day), as well as other causes of liver, kidney or heart diseases. Physical evaluation will include weight, height, measures of waist/hip ratio, measure of blood pressure. At each time point, body composition will be measured by dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer). Resting metabolic rate will be evaluated after a one-hour resting period in supine position. Oxygen consumption (VO2) and carbon dioxide production (VCO2), monitored over 30 min by using an open-circuit ventilated-canopy system (Deltatrac II monitor, Datex Instrumentarium Corp., Helsinki, Finland) calibrated with a reference gas. Blood samples will be obtained systematically for biological parameters including lipids (cholesterol, HDL-Chol, TG), insulin and glucose values and OGTT (enabling the determination of insulin sensitivity parameters, adipokines and inflammatory parameters such as leptin, adiponectin, IL-6, TNF alpha, SAA, hsCRP. Serum will be kept for all supplementary measures. The histopathological evaluation of subcutaneous adipose tissue will be performed to evaluate the adipocyte size and the degree of tissue inflammation. Stools samples will be collected for metagenomic studies. In addition, blood, urine and fecal water samples will be collected and frozen for subsequent metabonomic analysis, and fecal samples for metaproteomic assessment of the microbiota.

Interventions

OTHERCaloric transition

6 week low calorie diet followed by 6 week stabilization period

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
CollaboratorOTHER
Pierre and Marie Curie University
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
Ceprodi S.A. Kot
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. BMI 27 to 38 kg/m2 2. age: 25 to 65 years. 3. non diabetic subjects 4. fasting glycemia \< 1,26 g/l

Exclusion criteria

1. SGOT ou SGPT \> 2.5x normale 2. Glycemia \> 1,26 g/l 3. any other health problem or chronic treatment

Design outcomes

Primary

MeasureTime frameDescription
weight loss
intestinal microbiota genesidentify new intestinal microbiota at basal levels and follow their evolution during the dietary program by using a sequence based method (SOLiD™ System: a massively sequencing platform).
Body fat massusing dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer)
Food intakeusing 7 day dietary records at each time point

Secondary

MeasureTime frameDescription
plasma glucose
adipose tissue genesMicroarray

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026